Is India Pioneering an Indigenous Multi-Stage Malaria Vaccine 'AdFalciVax'?
Click to start listening
Synopsis
Discover how India is making strides in malaria prevention with the indigenous AdFalciVax. This groundbreaking multi-stage vaccine promises to change the landscape of malaria treatment and control. Join us in exploring its innovative approach and the potential impact on public health.
Key Takeaways
- AdFalciVax is an indigenous malaria vaccine candidate from India.
- It targets two stages of the Plasmodium falciparum parasite.
- The vaccine shows promise for broader immunity.
- It remains stable at room temperature for over nine months.
- Developed in line with the 'Make in India' initiative.
New Delhi, July 20 (NationPress) India has made a significant advancement in combating malaria with the creation of a new homegrown vaccine candidate known as AdFalciVax.
This innovative vaccine is being developed by the Indian Council of Medical Research (ICMR), through its affiliates RMRC Bhubaneswar and the National Institute of Malaria Research (NIMR), in collaboration with the Department of Biotechnology’s National Institute of Immunology (DBT-NII).
AdFalciVax is a groundbreaking malaria vaccine that targets two crucial stages of Plasmodium falciparum, the parasite responsible for the most lethal form of malaria.
Unlike most current vaccines that focus on a single stage of the parasite’s life cycle, AdFalciVax aims to deliver enhanced and longer-lasting protection by addressing both the human infection phase and the transmission stage via mosquitoes.
Initial laboratory tests have yielded promising results. Researchers are optimistic that it could provide multiple advantages over existing vaccines like RTS,S/AS01 and R21/Matrix-M.
These advantages encompass broader immunity, minimized chances of the parasite avoiding the immune response, and enhanced long-term protection.
Moreover, the vaccine remains stable for over nine months at room temperature, facilitating easier storage and transportation, especially in tropical climates.
It also employs cost-effective components such as alum, a common adjuvant in vaccines.
Currently in the preclinical phase, if all goes well, the vaccine could be ready for public deployment within approximately seven years.
This timeline includes production under stringent safety protocols, clinical trials, and regulatory approvals.
A noteworthy innovation of AdFalciVax is its formulation using Lactococcus lactis, a safe and established bacterium utilized in vaccine development.
The vaccine is designed to protect individuals from illness while simultaneously curbing the spread of malaria within communities.
The ICMR intends to license the vaccine technology to other organizations and manufacturers under non-exclusive agreements.
This approach allows multiple companies to contribute to vaccine production, expediting access to a larger population upon approval.
AdFalciVax is being developed entirely within India, reinforcing the government’s 'Make in India' initiative.
Point of View
It is crucial to highlight India's commitment to public health through innovative solutions like AdFalciVax. This vaccine embodies the essence of self-reliance and scientific advancement, aligning with our national goals. It is imperative to support such initiatives that promise to significantly impact malaria control and improve community health across the nation.
NationPress
20/07/2025
Frequently Asked Questions
What is AdFalciVax?
AdFalciVax is an indigenous malaria vaccine candidate developed in India that targets two key stages of the Plasmodium falciparum parasite.
Who is developing AdFalciVax?
AdFalciVax is being developed by the Indian Council of Medical Research (ICMR) in collaboration with several institutes.
What are the advantages of AdFalciVax?
The vaccine offers broader protection, reduces the chances of the parasite escaping the immune response, and provides improved long-term immunity.
How long will it take for AdFalciVax to be available to the public?
If successful, AdFalciVax could be ready for public use in approximately seven years after going through necessary trials and approvals.
What makes AdFalciVax unique?
AdFalciVax targets both human infection and transmission stages of malaria, making it more comprehensive than existing vaccines.
